Analyst Price Targets — IOVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 1, 2026 8:40 am | — | Wells Fargo | $5.00 | $4.10 | StreetInsider | Iovanace Biotherapeutics (IOVA) Reiterated at Market Outperform by Citizens |
| June 1, 2026 8:40 am | — | National Bank | $5.00 | $4.10 | StreetInsider | Iovanace Biotherapeutics (IOVA) Reiterated at Market Outperform by Citizens |
| February 5, 2026 12:53 pm | Andrea Newkirk | Goldman Sachs | $2.00 | $2.44 | TheFly | Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs |
| May 16, 2025 8:43 am | David Dai | UBS | $2.00 | $1.66 | TheFly | Iovance Biotherapeutics downgraded to Neutral from Buy at UBS |
| February 28, 2025 11:49 am | — | Piper Sandler | $6.00 | $4.24 | TheFly | Iovance Biotherapeutics price target lowered to $6 from $7.50 at Piper Sandler |
| January 31, 2025 11:40 am | Joseph Catanzaro | Piper Sandler | $7.50 | $5.85 | TheFly | Iovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler |
| October 24, 2024 3:53 am | David Dai | UBS | $17.00 | $9.82 | StreetInsider | UBS Starts Iovanace Biotherapeutics (IOVA) at Buy |
| August 9, 2024 7:56 am | Benjamin Burnett | Stifel Nicolaus | $11.50 | $3.97 | StreetInsider | Iovanace Biotherapeutics (IOVA) PT Lowered to $23 at Stifel |
| August 9, 2024 6:35 am | Colleen Kusy | Robert W. Baird | $12.00 | $3.97 | StreetInsider | Iovanace Biotherapeutics (IOVA) PT Lowered to $24 at Baird |
| July 29, 2024 2:11 am | Joseph Catanzaro | Piper Sandler | $10.00 | $9.25 | StreetInsider | Piper Sandler Downgrades Iovanace Biotherapeutics (IOVA) to Neutral |
Latest News for IOVA
SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 16, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options…
Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip was attributed to one-off events, not demand weakness. Gross margin was impacted by temporary costs but is expected to improve to 50%+ as internal manufacturing scales and opex reductions take effect.
The biotech is clearly innovative, but sometimes that's not enough.
Heartflow leverages AI-enabled software to dominate the non-invasive coronary diagnostic market, backed by a stable base of over 1,450 accounts. Iovance Biotherapeutics is pioneering personalized TIL therapies for cancer, backed by centralized manufacturing and significant revenue growth from its lead products.
Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IOVA.
U.S. House Trading
No House trades found for IOVA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.